Biodesix Q3 2026: Guidance Cut Overshadows Volume Growth
As seen on the 24/7 Wall St. homepage on November 5, 2026.
Biodesix cut its full-year outlook to $101 million to $103 million, blaming an understaffed sales force and unexpected primary care seasonality. Revenue missed consensus by 12.5%, and for a $208 million company that guidance cut outweighs the 24% rise in test volumes.
Continue ReadingShow less
Biodesix reported Q3 2026 revenue of $24.04 million, missing expectations of $27.49 million. Even as total revenue grew 10.4% year over year, the shortfall was wide enough to force a revision to the full-year outlook, which management trimmed to a range of $101 million to $103 million.
CEO Scott Hutton pointed to two operational problems as the principal causes. Fewer sales representatives were contributing than planned, which constrained new physician and account growth. On top of that, primary care ordering proved more seasonal than the company expected, pulling down volumes from otherwise stable customers. A third drag came from delayed project starts in the Development Services segment, which pushed revenue recognition into future periods.
The underlying diagnostic testing business offered some relief. Test volumes climbed 24% to 19,400, and gross margin held at 81%, supported by laboratory workflow efficiencies that lowered the cost per test. The GAAP EPS loss of $0.75 came in line with estimates.
Sponsored
Management struck a cautiously optimistic tone about the fourth quarter, noting that October produced the strongest month of new physician acquisition all year and that the company is entering Q4 with an expanded sales organization. The revised full-year guidance midpoint implies roughly 15% growth over 2025, and the company said it expects to continue making progress toward profitability while maintaining gross margins of approximately 80%.
Longer-term pipeline activity continued in parallel with the near-term turbulence. Biodesix highlighted a radiomics-based lung nodule risk assessment test developed with Vanderbilt University, with commercial availability anticipated in 2028, as well as two MRD assay programs being validated with Memorial Sloan Kettering Cancer Center. Real-world evidence from the CLARIFY study covering more than 2,000 patients was also presented at CHEST 2026, reinforcing clinical utility for the Nodify Lung platform.
Mentioned: BDSX